Cue Biopharma is trading 5.2% down at $23.32 after reversing an early pre-market rebound.
- No clear company-specific announcement was identified for August 21, 2026.
- Its latest major update, the August 14 second-quarter report, highlighted the CUE-221 FDA submission, a $50 million private placement, and leadership appointments.
- The broader market and biotech sector are higher, while the decline remains unexplained and may reflect continued selling after sharp losses earlier this week.